Jonathan Trent on Trabectedin for Soft Tissue Sarcoma

Article

Jonathan Trent, MD, PhD, associate director for clinical research, director of the Sarcoma Medical Research Program at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, discusses the approval of trabectedin to treat patients with soft tissue sarcoma. 

Jonathan Trent, MD, PhD, associate director for clinical research, director of the Sarcoma Medical Research Program at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, discusses the approval of trabectedin (Yondelis) to treat patients with soft tissue sarcoma. 

The FDA approved trabectedin in October 2015 for patients with liposarcoma and leiomyosarcoma who were previously treated with chemotherapy that included an anthracycline. 

The approval was based on a large, randomized study that found trabectedin was superior to dacarbazine chemotherapy in terms of response rates, duration of response, overall survival, and progression-free survival. 

Related Videos
MPN-Associated Anemia: What Nurses Should Look Out For
Cancer-Related Cognitive Impairment
Charina Toste
Lindsey Lyle
Alyssa Ridad
Yelena Shames
Johanna Garibaldi
Elizabeth Cullen
Shivani Gopalsami
Related Content
© 2023 MJH Life Sciences

All rights reserved.